Apollomics Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium Posted on 2023-04-112023-09-28 by maxproadmin More >>
Apollomics Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq Posted on 2023-03-302023-05-30 by maxproadmin More >>
Apollomics Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations Posted on 2022-11-152023-01-07 by maxproadmin More >>